Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jdermsci.2018.04.012 | DOI Listing |
JMIR Res Protoc
February 2024
Department of Pharmacy, Kobe University Hospital, Kobe, Japan.
Background: Rituximab, an anti-CD20 monoclonal antibody, can cause infusion reactions (IRs), especially during the initial rituximab infusion therapy. Generally, patients are administered a histamine H-receptor antagonist before the rituximab infusion, along with an antipyretic analgesic, to prevent or reduce IRs. Multiple retrospective case-control studies indicate that the second generation of histamine H-receptor antagonists might be more effective than the first generation in suppressing IRs caused by the rituximab infusion.
View Article and Find Full Text PDFClin Ophthalmol
November 2023
Ocular Surface Service, Lomas de San Isidro Medical Group, Buenos Aires, Argentina.
Purpose: To study the efficacy and toxic effects of bepotastine besilate 1.5% preservative-free (BB-PF) and olopatadine 0.2% BAK-preserved (OL-BAK) drops on the ocular surface of patients with allergic conjunctivitis.
View Article and Find Full Text PDFIndian J Dermatol Venereol Leprol
November 2023
Department of Pharmacology, Sri Ramachandra Medical College & Research Institute, Chennai, Tamil Nadu, India.
Background Urticaria is a common skin disease which often causes impairment in the quality of life. The ideal drug for chronic urticaria would have antihistaminic and anti-inflammatory actions. Bepotastine besilate is a recently approved novel anti-allergic agent with multiple mechanisms of action; levocetirizine is a potent and selective second-generation H1 receptor antagonist used in the treatment of urticaria.
View Article and Find Full Text PDFIndian J Dermatol
January 2021
Department of Dermatology, Bankura Sammilani Medical College, Kenduadihi, Bankura, West Bengal, India.
Asian Pac J Allergy Immunol
December 2024
Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Hospital, Seoul, Korea.
Background: The efficacy of rupatadine for the treatment of AR has been confirmed in numerous clinical studies, however there are very few studies on asian patients.
Objective: To assess the safety and efficacy of rupatadine fumarate in the treatment of Korean perennial allergic rhinitis (PAR) patients.
Methods: A multicenter, double-blind, randomized, placebo-controlled, comparative study of rupatadine fumarate and bepotastine besilate was conducted.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!